NIR spectroscopy device predicts diabetic wound healing

Philadelphia-- A new device, based on diffuse near-infrared (NIR) spectroscopy, promises to change chronic wound management.  Diffuse near-infrared spectroscopy allows tissue to be non-invasively analyzed by measuring its optical absorption and scattering coefficients.

Philadelphia-- A new device, based on diffuse near-infrared (NIR) spectroscopy, promises to change chronic wound management. Complex wounds affect more patients in the U.S. than heart attack and stroke combined, yet there are currently no established methods for early detection of wound healing, or for precise identification of healing progress. But researchers at Drexel University have created a prototype that measures the level of oxygenated and deoxygenated hemoglobin near a wound and compares it to a control/non-wound site of the same patient. Based on study results, the time course of oxygenated hemoglobin change was found to be a strong indicator of wound healing.

Diffuse near-infrared spectroscopy allows tissue to be non-invasively analyzed by measuring its optical absorption and scattering coefficients. A "diagnostic window" exists at near-infrared wavelengths (650-900 nm), allowing determination of tissue optical properties at significant depths, because light is able to penetrate several centimeters into tissue due to low absorption of hemoglobin. The absorption spectra of oxy-hemoglobin and deoxy-hemoglobin are distinct at near-infrared wavelengths, and with proper instrumentation, the absolute concentrations of each can be determined.

The device prototype has been developed and tested over the course of several years. It is controlled by software from a laptop computer and can move from patient to patient in a busy clinical setting. Measurements can be taken at any spot within or around the wound and take seconds to complete. Results are displayed on the computer screen almost instantly following the measurement. Improved prototypes are being designed. In its final stages, the device will become more portable.

Promised advantages of the Drexel technology include:

  • Fast quantitative method for characterizing diabetic and pressure ulcers.
  • Quantitative assessment of ischemic tissue in a broad variety of clinical applications.
  • Ability to predict wound healing due to therapy at least 50% earlier (four weeks as opposed to eight weeks or more) compared to conventional methods.

The research team included Elisabeth S. Papazoglou, Ph.D., and Leonid Zubkov, Sc.D., of Drexel University's School of Biomedical Engineering, Science and Health Systems, and Michael S. Weingarten, M.D., MBA, FACS of the Drexel University College of Medicine.

About 150,000 amputations a year result from complex wounds, while about 80,000 are attributed to diabetes and peripheral arterial disease.

More in Biophotonics Tools